Comparison of apatinib and capecitabine (Xeloda) with capecitabine (Xeloda) in advanced triple-negative breast cancer as third-line therapy: A retrospective study. Issue 36 (September 2018)

• Record Type: Journal Article
• Authors: Li, Yi-Hui; Zhou, Yang; Wang, Yu-Wei; Tong, Ling; Jiang, Run-Xue; Xiao, Lei; Zhang, Guang-Ju; Xing, Shu-Shan; Qian, Fang; Feng, Jing-Qi; Zhao, Ya-Ling; Wang, Jian-Gong; Wang, Xiao-Hong
• Other Names: Staege. Martin S. section editor.
• Is Part Of: Medicine. Volume 97:Issue 36(2018)
• Publication Date: 2018-09
• Subjects: advanced triple-negative breast cancer -- apatinib -- capecitabine -- third-line therapy; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000012222
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract : Abstract: The treatment of advanced triple-negative breast cancer, which failed in first-line or second-line therapy, is a significant challenge. We conducted this retrospective study to explore the efficacy and safety of apatinib and capecitabine as the third-line treatment for advanced triple-negative breast cancer. This retrospective study involved 44 advanced triple-negative breast cancer patients who failed in first-line or second-line therapy in Tangshan People's Hospital from January 2016 to February 2017. Twenty-two patients received apatinib and capecitabine, while 22 patients were treated with capecitabine monotherapy as third-line therapy. The progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and adverse events were compared between 2 groups. The apatinib and capecitabine group exhibited a higher PFS than capecitabine group ( P = .001). Meanwhile, ORR and DCR in apatinib and capecitabine group were better than in capecitabine group ( P = .042; .016). The 2 groups showed no significant difference in adverse events except degree I-II bleeding ( P = .021). Both the apatinib and capecitabine and the capecitabine regimens revealed good tolerability. The apatinib and capecitabine regimen can achieve a better efficacy and similar serious adverse events compared with capecitabine regimen as the third-line treatment for advanced triple-negative breast cancer.